Oral Drug Delivery Resources

  1. Development Of Next Gen Sustained Release Solutions For Pain Management 2/22/2023

    A TheraPEA™ polymer based injectable formulation designed to deliver the same dose of Triamcinolone Acetonide (TAA) as in Zilretta® has shown promising results in a series of pre-clinical studies.

  2. Advancements In GLP-1 Analog Formulation: Overcoming Challenges 2/3/2025

    Oral GLP-1 formulations represent a groundbreaking advance in obesity treatment to offer improved patient comfort and adherence while expanding the therapeutic market.

  3. Crystallization Process Development: Peptide Crystallization 1/24/2022

    Whether performed during formation of an API or as a means to purify intermediates, achieving control of nucleation and crystal growth is critical to designing a successful peptide crystallization process.

  4. Reducing Environmental Impact At All Stages Of The Medicine Journey

    Explore how utilizing technologies like AI and digital twinning can inform decision-making at the R&D stage and how to optimize the delivery of the final drug product to patients with greener logistics.

  5. How To Leverage Modeling And Simulation In The Candidate Development Stage

    Modeling and simulation provides another way to predict the clinical performance of a molecule, based on a robust and holistic approach, before investing the required time and money.

  6. Less Mess, Less Stress, Best Expressed: An Alternative To Spray Drying 7/16/2024

    Although well-established processes, spray drying and hot-melt extrusion can be outperformed in bioavailability, cost-savings, manufacturing speed, environmental impact, and more.

  7. How Approved Drugs Have Evolved Since The '70s

    Drugs have become more lipophilic and complex in structure over time. Innovative strategies are needed to improve the bioavailability of these new drugs.

  8. A Solvent-Free, Fusion-Based ASD Manufacturing Process 3/5/2024

    Explore a solvent-free alternative for the production of amorphous solid dispersions (ASDs) that not only improves manufacturability but also reduces the carbon footprint of ASD manufacturing.

  9. Formulation Development From Preclinical To First-In-Human 1/24/2022

    A compound with poor biopharmaceutical properties or improper formulation design could lead to a delay in the project or even program termination.

  10. Integrated First-In-Human Services To Streamline End-To-End Development And Manufacturing 6/1/2022

    Lonza’s SimpliFiH®️ Solutions offering is designed to simplify and accelerate the development pathway, even for APIs with challenging properties, such as low aqueous solubility and poor bioavailability.